Is the fine‑needle aspiration (FNA) of a right thyroid lobe nodule, showing a cellular and atypical follicular lesion of undetermined significance (Bethesda category III), benign or malignant, and what clinical follow‑up is recommended if surgical excision is not planned?

Bethesda Category III (AUS/FLUS) Thyroid Nodule: Malignancy Risk and Management

A Bethesda category III nodule is neither definitively benign nor malignant—it carries a 25-40% malignancy risk and requires risk stratification using ultrasound features and cytologic subtype to determine whether to proceed with surgery, repeat FNA, or surveillance.

Understanding the Malignancy Risk

Bethesda III nodules represent a heterogeneous group with variable cancer risk. The malignancy rate in surgically excised Bethesda III nodules ranges from 27-42% across multiple studies 1, 2, 3, 4. This is substantially higher than the originally estimated 5-15% risk, making careful risk stratification essential.

The cytologic subtype matters significantly: Nuclear atypia (suggesting papillary thyroid carcinoma features) carries up to 50% malignancy risk and is an independent predictor of cancer 2, 5. In contrast, follicular-pattern atypia (FLUS) has a lower malignancy rate of approximately 40% 2.

Management Algorithm Based on Guidelines

The 2016 AACE/ACE guidelines provide clear direction for Bethesda III management 6:

For Low-Risk AUS/FLUS Nodules:

• Consider conservative management if favorable features are present:

  • Low-risk ultrasound characteristics
  • Small nodule size
  • No concerning personal/family history

• Repeat FNA is the preferred next step for further cytologic assessment 6

• Review samples with an experienced cytopathologist 6

For High-Risk Features:

• Surgery is recommended when unfavorable characteristics exist 6
• Thyroid lobectomy plus isthmusectomy is the standard approach 6

Critical Risk Stratification Factors

Ultrasound features are essential for decision-making, though their predictive value has limitations in this specific category:

High-Risk Ultrasound Features (favor surgery):

• Microcalcifications 3, 7
• Marked hypoechogenicity 3
• Taller-than-wide orientation 3
• Irregular/lobulated margins 3
• Homogeneous solid echotexture 7
• Thickened rim 7

Important caveat: Recent evidence shows that while ACR TI-RADS and ultrasound features help predict papillary thyroid carcinoma, they perform poorly for follicular carcinomas 1. Approximately 80% of follicular carcinomas and 50% of all follicular cancers show low-suspicion ultrasound features 1, creating a diagnostic blind spot.

Cytologic Subtype (critical predictor):

• Nuclear atypia: 50% malignancy rate, independent predictor of cancer (adjusted OR 3.96) 5
• Follicular-pattern atypia (FLUS): 40% malignancy rate 2

Clinical Factors:

• TSH >4.5 mIU/L: 35% malignancy rate 3
• Nodule size <2 cm: 34.6% malignancy rate 3

Note: Inflammatory markers (NLR, PLR) do NOT predict malignancy in Bethesda III nodules 5.

Repeat FNA: Utility and Outcomes

Repeat FNA reclassifies approximately 79% of Bethesda III nodules to different categories 8:

• 57% reclassified as benign
• 11% as follicular neoplasm
• 6% as suspicious/malignant
• 40% remain AUS/FLUS 2, 8

The diagnostic utility of repeat FNA is 50% for obtaining a definitive diagnosis 2. However, repeat FNA does NOT reduce the overall malignancy rate—it remains approximately 33% whether surgery is performed after initial or repeat FNA 8.

Recommended Management Pathway

For nodules with nuclear atypia OR high-risk ultrasound features (ACR TI-RADS 5, multiple suspicious features):

• Proceed directly to surgery (thyroid lobectomy) 6, 5
• Frozen section is usually not helpful 6

For nodules with follicular-pattern atypia AND low-risk ultrasound features:

• Repeat FNA in 3-6 months 6
• If repeat shows benign features: surveillance with ultrasound
• If repeat remains AUS/FLUS or upgrades: consider surgery

For nodules with favorable clinical features (low TSH, no family history, low-risk ultrasound):

• Close clinical follow-up with ultrasound surveillance is acceptable 6
• This requires multidisciplinary discussion and informed patient consent 6

Common Pitfalls to Avoid

1. Do not assume low ultrasound risk excludes malignancy in FLUS nodules—follicular carcinomas frequently appear benign on ultrasound 1

2. Do not rely on inflammatory markers (NLR, PLR) for risk stratification—they lack predictive value 5

3. Do not perform unnecessary surgeries on all Bethesda III nodules—approximately 60-70% are benign 3, 4

4. Do not ignore the cytologic subtype—nuclear atypia has 4× higher odds of malignancy than other subtypes 5

5. Recognize that repeat FNA may still yield AUS/FLUS in 40% of cases 2—this should not delay surgery if other high-risk features are present